Your Complete Guide to Wegovy BMI Requirements
Understanding Wegovy BMI Requirements for Prescription Weight Loss
Wegovy BMI requirements are clearly defined by UK licensing regulations to ensure safe and appropriate prescription weight loss treatment. Adults qualify with a BMI of 30 or above, whilst those with a BMI between 27-29.9 can access Wegovy if they have weight-related health conditions such as high blood pressure, type 2 diabetes, or sleep apnoea. These Wegovy BMI requirements align with NICE guidance TA875, which recommends semaglutide for weight management with specialist support.
The prescription weight loss approach with Wegovy differs significantly from over-the-counter options because it requires clinical assessment to verify BMI eligibility and medical suitability. Adolescents aged 12 and above with body weight over 60kg may also qualify if their BMI corresponds to 30 or above in adults. This targeted approach ensures Wegovy BMI requirements match clinical need, making prescription weight loss both safe and effective when combined with lifestyle modifications.
Wegovy Pricing Structure and BMI-Based Treatment Value
Understanding Wegovy BMI requirements helps justify the prescription weight loss investment, with starter treatment beginning at £79.99 for the 0.25mg dose using code FIRST40 at checkout. Our structured pricing reflects the dose escalation protocol required for safe and effective treatment, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the maintenance 2.4mg dose (£209.99). Returning customers can use code DOSE25 for ongoing prescription weight loss treatment.
For patients meeting Wegovy BMI requirements who prefer structured supply, our bundle options provide convenience and continuity. The Intro Duo combining 0.25mg and 0.5mg costs £169.99, whilst the Progress Trio including 0.5mg, 1mg and 1.7mg is £369.99. These bundles ensure uninterrupted prescription weight loss treatment during the crucial first months when establishing the therapeutic dose according to your BMI and clinical response.
Clinical Evidence Supporting Wegovy BMI Requirements
The Wegovy BMI requirements are based on robust clinical evidence from the STEP trial programme. In STEP 1, patients taking Wegovy alongside a reduced-calorie diet and increased physical activity achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). These results validated the BMI thresholds used for prescription weight loss eligibility.
STEP 5 demonstrated sustained prescription weight loss benefits, with patients maintaining approximately clinically studied weight loss at two years. The SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events, reinforcing why Wegovy BMI requirements include patients with comorbidities at lower BMI thresholds.
How Wegovy Works for Patients Meeting BMI Requirements
Wegovy functions as a GLP-1 receptor agonist, mimicking a natural hormone that regulates appetite and food intake in patients meeting the BMI requirements for prescription weight loss. The medication works directly on brain appetite centres, reducing hunger signals and promoting feelings of fullness after smaller meals. This mechanism addresses the physiological challenges of weight management that often make traditional diet and exercise approaches insufficient for those qualifying under Wegovy BMI requirements. The once-weekly injection provides consistent appetite regulation throughout the week, supporting sustained prescription weight loss efforts. Unlike short-term interventions, Wegovy's hormonal approach helps patients naturally reduce calorie intake whilst maintaining nutritional balance.
Simple Ordering Process for Wegovy BMI Assessment
Starting prescription weight loss treatment begins with our 3-minute online clinical assessment, which evaluates your BMI against Wegovy requirements alongside medical history and current medications. Our qualified prescribers review your assessment within 3 working days (express 24-hour service available), ensuring you meet the BMI criteria and have no contraindications to semaglutide treatment. Once approved, your prescription-only medicine is prepared by our GPhC-registered pharmacy (#9012878) and dispatched via next-day cold-chain delivery. The temperature-controlled packaging maintains Wegovy's stability during transport, arriving ready for immediate refrigerated storage. This streamlined process removes barriers between BMI assessment and starting your prescription weight loss journey.
Wegovy Storage and Practical BMI Treatment Considerations
Meeting Wegovy BMI requirements is just the beginning - successful prescription weight loss requires proper medication storage and administration technique. Wegovy must be stored in the refrigerator at 2-8°C before first use, though it remains stable at room temperature below 30°C for up to 6 weeks once removed from cold storage. The FlexTouch pen design simplifies weekly injections, with clear dose markings that correspond to the escalation schedule required for all patients meeting BMI criteria. Dose escalation cannot be skipped regardless of your starting BMI, as the gradual increase minimises gastrointestinal side effects whilst building therapeutic effectiveness. The prescribed dose schedule progresses systematically from 0.25mg through to the 2.4mg maintenance dose over 16 weeks.
BMI Categories and Prescription Weight Loss Eligibility
Wegovy BMI requirements create clear categories for prescription weight loss eligibility, with Class I obesity (BMI 30-34.9) representing the most common qualifying group. Class II obesity (BMI 35-39.9) and Class III obesity (BMI ≥40) patients typically show enhanced responses to semaglutide treatment, reflecting the medication's effectiveness across the BMI spectrum. The overweight category (BMI 27-29.9) requires additional weight-related comorbidities for Wegovy eligibility, recognising that prescription weight loss benefits extend beyond BMI numbers alone.
These BMI thresholds for prescription weight loss reflect evidence-based medicine, where treatment intensity matches clinical need and potential benefit. Patients closer to the BMI requirements threshold should expect thorough assessment of comorbidities and previous weight management attempts. The structured approach ensures prescription weight loss treatment reaches those most likely to benefit whilst maintaining clinical safety standards.
Start Your Prescription Weight Loss Journey Today
Ready to discover if you meet Wegovy BMI requirements for prescription weight loss treatment? Our clinical assessment takes just 3 minutes and provides immediate feedback on your eligibility for this MHRA-licensed medication. New customers can use code FIRST40 at checkout, whilst returning patients save with code DOSE25 on continuing treatment. Visit https://everydaymeds.co.uk/collections/wegovy to begin your assessment and join thousands of patients successfully managing their weight with clinical support. Our GPhC-registered pharmacy (#9012878) ensures every prescription meets the highest safety standards whilst delivering the convenience of next-day home delivery. Don't let BMI requirements uncertainty delay your prescription weight loss journey - start your assessment today.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
